MLICM
XBIT icon

Metropolitan Life Insurance Company (MetLife)’s XBiotech XBIT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,457
Closed -$57.7K – 2832
2021
Q3 		$57.7K Buy
+4,457
New +$71K ﹤0.01% 2741
2020
Q4 		– Sell
-4,580
Closed -$87.4K – 2577
2020
Q3 		$87.4K Hold
4,580
– – ﹤0.01% 2292
2020
Q2 		$62.8K Buy
+4,580
New +$64.4K ﹤0.01% 2474
2020
Q1 		– Sell
-6,655
Closed -$124K – 2547
2019
Q4 		$124K Buy
+6,655
New +$85.7K ﹤0.01% 2200

Other funds holding XBIT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s XBIT Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of XBiotech (XBIT) in Q4 2021, closing a stake of 4,457 shares — an estimated $57.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in XBIT in Q4 2019 and held it in 4 quarters. The position peaked at $124K in Q4 2019. 61 funds tracked by Wall St. Rank hold XBIT as of Q4 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining XBiotech position as of Q4 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 4,457 XBiotech shares in Q4 2021, an estimated $57.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in XBiotech in Q4 2019 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s XBiotech position peaked at $124K in Q4 2019.
  • 61 funds tracked by Wall St. Rank held XBiotech as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.